Search results for "Daclizumab"
showing 5 items of 5 documents
GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
2018
ObjectiveTo describe a case of glial fibrillary acidic protein (GFAP)α immunoglobulin G (IgG)-associated encephalitis in a patient referred to us with MS on daclizumab treatment and to summarize characteristics of 5 additional recent German MS cases of serious encephalitis along with a previously published American case of CNS vasculitis associated with daclizumab.MethodsEvaluation of cause, clinical symptoms, and treatment response.ResultsThe 6 patients included 4 women and 2 men. The median age at onset was 38 years (range 32–51 years). Clinical presentation was marked by progressing neuropsychologic and/or neurologic deficits. Additional drug rash with eosinophilia was seen in 3 patients…
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
2019
Background: Daclizumab is a monoclonal antibody that binds the high-affinity interleukin-2 receptor and was approved for the treatment of relapsing multiple sclerosis. Due to severe inflammatory brain disorders, the approval was suspended in March 2018. Objective and Methods: This retrospective cohort study summarizes clinical, laboratory, radiological, and histological findings of seven patients who developed meningo-/encephalitis after daclizumab therapy. Results: Patients presented with encephalitis and/or meningitis and suffered from systemic symptoms such as fever (5/7), exanthema (5/7), or gastrointestinal symptoms (4/7). Secondary autoimmune diseases developed. Blood analysis reveale…
Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in li…
2008
Introduction. Long-term steroid administration may predispose liver transplant recipients to infectious and metabolic complication. Maintaining effective immunoprophylaxis while minimizing the negative consequences of steroid therapy could be a key factor in improving clinical outcomes.Methods. Six hundred two patients were randomized to receive tacrolimus (TAC) immunosuppression with a single-steroid bolus and two doses of daclizumab (DAC) or mycophenolate mofetil (MMF).Results. The incidence of biopsy-proven acute rejection was 19.7% in the TAC/DAC group and 16.2% in the TAC/ MMF group (ns). Three-month patient and graft survival were similar. Steroid use at month-3 was low at 5.5% in the…
An anti-interleukin-2 receptor drug attenuates T- helper 1 lymphocytes-mediated inflammation in an acute model of endotoxin-induced uveitis.
2014
The aim of the present study was to evaluate the anti-inflammatory efficacy of Daclizumab, an anti-interleukin-2 receptor drug, in an experimental uveitis model upon a subcutaneous injection of lipopolysaccharide into Lewis rats, a valuable model for ocular acute inflammatory processes. The integrity of the blood-aqueous barrier was assessed 24 h after endotoxin-induced uveitis by evaluating two parameters: cell count and protein concentration in aqueous humors. The histopathology of all the ocular structures (cornea, lens, sclera, choroid, retina, uvea, and anterior and posterior chambers) was also considered. Enzyme-linked immunosorbent assays of the aqueous humor samples were performed t…
STUDIO CLINICO RANDOMIZZATO DEL THYMOGLOBULIN/ALEMTUZUMAB VS. THYMOGLOBULIN/DACLIZUMAB COME INDUZIONE COMBINATA (CON ELIMINAZIONE DI CORTICOSTEROIDI)…
2009
Introduzione: Uno studio prospettico randomizzato che valuta l’efficacia del Thymoglobulin (Thymo) in combinazione con l’Alemtuzumab (CH1) versus Daclizumab (DAC) deve ancora essere riportato. Materiali e metodi: Da Febbraio 2006 a Ottobre 2008, 148 riceventi di trapianto di rene da donatore cadavere (DC) e da donatore vivente (DV) HLA non identico furono randomizzati in due gruppi (N=74 per gruppo): il gruppo A (THYMO/CH1) e il gruppo B (THYMO/DAC) con ridotto dosaggio di tacrolimus (livelli target di 6-8 ng/ml), micofenolato sodico (EC-MPS) 360 mg due volte al giorno per il gruppo A e 720 mg due volte al giorno per il gruppo B ed eliminazione dei corticosteroidi ad una settimana dall’inte…